ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR...
Pharmaceutical
Yield10 Bioscience Announces Delisting from Nasdaq
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company,...
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Eli Lilly’s and AstraZeneca’s Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops...
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals,...
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived...
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that...
Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting...
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic...
PillSafe Provides a Solution to the Opioid Epidemic’s $1 Trillion-Plus Impact on the US Economy
As federal and state governments implement far-ranging programs to address the crisis, PillSafe offers a technology-based solution that ensures patients...
GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease
Collaboration seeks to advance precision care by providing an alternative, non-invasive approach to the assessment of coronary physiology. Both companies...
GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease
Collaboration seeks to advance precision care by providing an alternative, non-invasive approach to the assessment of coronary physiology. Both companies...
Anumana Appoints Harry S. Palmin as CFO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry...
Anumana Appoints Harry S. Palmin as CFO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry...
Jaguar Health Reports First Quarter 2024 Financial Results
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /...
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to...
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline...
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused...